Argonde C Van Harten1, Heather J Wiste2, Stephen D Weigand2, Michelle M Mielke2, Walter K Kremers2, Udo Eichenlaub2, Richard Batrla-Utermann2, Roy B Dyer2, Alicia Algeciras-Schimnich2, David S Knopman2, Clifford R Jack2, Ronald C Petersen2. 1. From the Departments of Neurology (A.C.V.H., M.M.M., D.S.K., R.C.P.), Health Sciences Research (H.J.W., S.D.W., M.M.M., W.K.K., R.C.P.), Laboratory Medicine and Pathology (R.B.D.), and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; Department of Neurology and Alzheimer Center Amsterdam UMC (A.C.V.H.), the Netherlands; and Roche Diagnostics (U.E., R.B.-U., A.A.-S.), Basel, Switzerland. VanHarten.Argonde@mayo.edu. 2. From the Departments of Neurology (A.C.V.H., M.M.M., D.S.K., R.C.P.), Health Sciences Research (H.J.W., S.D.W., M.M.M., W.K.K., R.C.P.), Laboratory Medicine and Pathology (R.B.D.), and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; Department of Neurology and Alzheimer Center Amsterdam UMC (A.C.V.H.), the Netherlands; and Roche Diagnostics (U.E., R.B.-U., A.A.-S.), Basel, Switzerland.
Abstract
OBJECTIVE: We studied interrelationships between CSF biomarkers and associations with APOE ε4 genotype, demographic variables, vascular variables, and clinical diagnosis in Olmsted County, Minnesota. METHODS: We included 774 Mayo Clinic Study of Aging participants (693 cognitively unimpaired [CU]; 71 with mild cognitive impairment [MCI]). CSF β-amyloid 42 (Aβ42), total tau (t-tau), and hyperphosphorylated tau (p-tau) were analyzed using Aβ42 CSF, t-tau CSF, and p-tau (181P) CSF electrochemiluminescence immunoassays. Bivariate mixture models were used to evaluate latent classes. We used linear regression models to evaluate independent associations of APOE ε4, demographic factors, cardiovascular risk, and diagnosis with CSF biomarker levels. Results were weighted back to the Olmsted County population. RESULTS: Interrelationships between CSF Aβ42 and p-tau/t-tau were consistent with 2 latent classes in the general population. In subgroup 1 (n = 547 [71%]), we found a strong positive correlation between Aβ42 and p-tau (ρ = 0.81), while the correlation was much smaller in group 2 (ρ = 0.26, n = 227 [29%]). Group 2 was associated with older age, APOE ε4 genotype, a diagnosis of MCI, and elevated amyloid PET. Overall, APOE ε4 genotype and MCI were associated with Aβ42, while age was associated with p-tau/t-tau. There were no associations with sex, education, or vascular risk. CONCLUSION: We hypothesize the population without dementia can be subdivided into participants with and without biological Alzheimer disease (AD) based on the combination of CSF Aβ42 and p-tau/t-tau (represented also by the p-tau/t-tau/Aβ42 ratio). In those without biological AD, common factors such as CSF dynamics may cause a positive correlation between CSF Aβ42 and p-tau/t-tau, while AD leads to dissociation of these proteins.
OBJECTIVE: We studied interrelationships between CSF biomarkers and associations with APOE ε4 genotype, demographic variables, vascular variables, and clinical diagnosis in Olmsted County, Minnesota. METHODS: We included 774 Mayo Clinic Study of Aging participants (693 cognitively unimpaired [CU]; 71 with mild cognitive impairment [MCI]). CSF β-amyloid 42 (Aβ42), total tau (t-tau), and hyperphosphorylated tau (p-tau) were analyzed using Aβ42 CSF, t-tau CSF, and p-tau (181P) CSF electrochemiluminescence immunoassays. Bivariate mixture models were used to evaluate latent classes. We used linear regression models to evaluate independent associations of APOE ε4, demographic factors, cardiovascular risk, and diagnosis with CSF biomarker levels. Results were weighted back to the Olmsted County population. RESULTS: Interrelationships between CSF Aβ42 and p-tau/t-tau were consistent with 2 latent classes in the general population. In subgroup 1 (n = 547 [71%]), we found a strong positive correlation between Aβ42 and p-tau (ρ = 0.81), while the correlation was much smaller in group 2 (ρ = 0.26, n = 227 [29%]). Group 2 was associated with older age, APOE ε4 genotype, a diagnosis of MCI, and elevated amyloid PET. Overall, APOE ε4 genotype and MCI were associated with Aβ42, while age was associated with p-tau/t-tau. There were no associations with sex, education, or vascular risk. CONCLUSION: We hypothesize the population without dementia can be subdivided into participants with and without biological Alzheimer disease (AD) based on the combination of CSF Aβ42 and p-tau/t-tau (represented also by the p-tau/t-tau/Aβ42 ratio). In those without biological AD, common factors such as CSF dynamics may cause a positive correlation between CSF Aβ42 and p-tau/t-tau, while AD leads to dissociation of these proteins.
Authors: J A Lucas; R J Ivnik; G E Smith; D L Bohac; E G Tangalos; N R Graff-Radford; R C Petersen Journal: J Clin Exp Neuropsychol Date: 1998-04 Impact factor: 2.475
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Clifford R Jack; Heather J Wiste; Terry M Therneau; Stephen D Weigand; David S Knopman; Michelle M Mielke; Val J Lowe; Prashanthi Vemuri; Mary M Machulda; Christopher G Schwarz; Jeffrey L Gunter; Matthew L Senjem; Jonathan Graff-Radford; David T Jones; Rosebud O Roberts; Walter A Rocca; Ronald C Petersen Journal: JAMA Date: 2019-06-18 Impact factor: 56.272
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen Journal: Alzheimers Dement Date: 2016-09-30 Impact factor: 21.566
Authors: Lilah M Besser; Michael L Alosco; Liliana Ramirez Gomez; Xiao-Hua Zhou; Ann C McKee; Robert A Stern; John Gunstad; Julie A Schneider; Helena Chui; Walter A Kukull Journal: J Neuropathol Exp Neurol Date: 2016-08-11 Impact factor: 3.685
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Neuroepidemiology Date: 2008-02-07 Impact factor: 3.282
Authors: Catherine Chiu; Miles C Miller; Ilias N Caralopoulos; Michael S Worden; Thomas Brinker; Zachary N Gordon; Conrad E Johanson; Gerald D Silverberg Journal: Fluids Barriers CNS Date: 2012-01-23
Authors: Oskar Hansson; Sylvain Lehmann; Markus Otto; Henrik Zetterberg; Piotr Lewczuk Journal: Alzheimers Res Ther Date: 2019-04-22 Impact factor: 6.982
Authors: Jonathan Graff-Radford; David T Jones; Heather J Wiste; Petrice M Cogswell; Stephen D Weigand; Val Lowe; Benjamin D Elder; Prashanthi Vemuri; Argonde Van Harten; Michelle M Mielke; David S Knopman; Neill R Graff-Radford; Ronald C Petersen; Clifford R Jack; Jeffrey L Gunter Journal: Neurobiol Aging Date: 2021-11-01 Impact factor: 4.673
Authors: Petrice M Cogswell; Heather J Wiste; Michelle M Mielke; Christopher G Schwarz; Stephen D Weigand; Val J Lowe; Terry M Therneau; David S Knopman; Jonathan Graff-Radford; Prashanthi Vemuri; Matthew L Senjem; Jeffrey L Gunter; Alicia Algeciras-Schimnich; Ronald C Petersen; Clifford R Jack Journal: Neurobiol Aging Date: 2022-05-26 Impact factor: 5.133
Authors: Emily C Edmonds; Denis S Smirnov; Kelsey R Thomas; Lisa V Graves; Katherine J Bangen; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi Journal: Neurology Date: 2021-08-10 Impact factor: 11.800
Authors: Vijay K Ramanan; Michael G Heckman; Timothy G Lesnick; Scott A Przybelski; Elliot J Cahn; Matthew L Kosel; Melissa E Murray; Michelle M Mielke; Hugo Botha; Jonathan Graff-Radford; David T Jones; Val J Lowe; Mary M Machulda; Clifford R Jack; David S Knopman; Ronald C Petersen; Owen A Ross; Prashanthi Vemuri Journal: Acta Neuropathol Date: 2022-04-12 Impact factor: 15.887
Authors: Argonde C van Harten; Heather J Wiste; Stephen D Weigand; Michelle M Mielke; Walter K Kremers; Udo Eichenlaub; Roy B Dyer; Alicia Algeciras-Schimnich; David S Knopman; Clifford R Jack; Ronald C Petersen Journal: Alzheimers Dement Date: 2021-07-26 Impact factor: 16.655
Authors: Katherine J Bangen; Denis S Smirnov; Lisa Delano-Wood; Christina E Wierenga; Mark W Bondi; David P Salmon; Douglas Galasko Journal: Alzheimers Res Ther Date: 2021-07-01 Impact factor: 6.982